Jaren Lerner, MD

Jaren Lerner, M.D. is part of Comprehensive Cancer’s team of medical oncologists that provide patient treatment in a supportive and caring environment.

EDUCATION
Dr. Jaren Lerner earned his medical degree from the Ross University School of Medicine in 2018. He completed a three-year internal medicine residency at the Eisenhower Medical Center in Rancho Mirage, California before completing a clinical fellowship in hematology and medical oncology at Louisiana State University, Shreveport. He also holds a Bachelor of Science in chemistry with a minor in Spanish from the University of British Columbia, Vancouver.

EXPERIENCE
Dr. Lerner is a medical oncologist and hematologist at Comprehensive Cancer Centers. He brings a wealth of experience from his previous role as an assistant professor at the University of Kentucky’s Division of Hospital Medicine, where he focused on clinical service as a hospitalist, managed complex inpatient cases with varied acute medical problems, delivered grand round lectures and supervised medical students and residents. During his time as resident physician of internal medicine at Eisenhower Medical Center, he gained extensive procedural experience with bedside ultrasound, worked with high acuity patients including geriatric patients with multiple comorbidities, taught and mentored third and fourth-year medical students and treated patients in the high-risk HIV community.

PERSONAL
Dr. Lerner loves spending time with his family. He met his wife during his medical training in Guadalajara, Mexico. Together, they have a 1-year-old son and a dog. They enjoy traveling, going to restaurants, live music, playing sports and exploring the outdoors. He is fluent in English and Spanish and maintains conversational proficiency in Portuguese.

PATIENT PHILOSOPHY
Dr. Lerner takes a shared decision-making approach to patient care. He meets his patients where they need him to, whether that is taking the lead by making recommendations and forming a treatment plan or providing information and allowing the patient to decide what route of treatment or observation they would like to take. Dr. Lerner welcomes questions and wants patients to feel heard and understood.

TREATMENT CENTER
Southern Hills

PUBLICATIONS
• Lerner J, Michel M, Iskandar A, et al. Age-related clinicopathologic features and survival in papillary serous uterine cancer patients older and younger than 70 – an exploratory analysis of a series of consecutive patients. J Clin Oncol 38: 2020. doi: 0.1200/JCO.2020.38.15_suppl.e18104
• Lerner J, Michel M, Dasanu CA. 5-azacitidine reversing “spent” phase polycythemia vera back to proliferative phase and need for phlebotomy. J Oncol Pharm Pract. 2020;26(5):1285-1288.
• Lerner J, Michel M, Dasanu CA. Relapsed refractory metastatic squamous cell cancer of anal canal in a patient with retroviral infection responding to cetuximab. J Oncol Pharm Pract. 2020;26(4):1025-1028.
• Michel Ocampo M, Lerner J, Tosonian S, Dasanu CA. Advanced papillary thyroid carcinoma responding to nivolumab. J Oncol Pharm Pract. 2021;27(2):453-456.
• Ocampo MM, Lerner J, Dasanu CA. Bluish-gray fingernail discoloration due to the use of nivolumab. J Oncol Pharm Pract. 2021;27(2):457-459.
• Dasanu CA, Iskandar AS, Hwang A, et al. Management and clinical outcomes in uterine malignant mixed Müllerian tumor: Lessons from a single-institution series. J Oncol Pharm Pract. 2020;26(3):688-691.
• Dasanu CA, Lerner J, Ocampo MM, et al. Advanced uterine papillary serous cancer: Could there be a role for newer targeted therapeutic approaches or immune checkpoint inhibitors? J Oncol Pharm Pract. 2021;27(5):1181-1185.
• Qureshi A, Michel M, Lerner J, Dasanu CA. Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opin Pharmacother. Published online July 15, 2021:1-12.